https://hieisai.com.ph/brush-for-freedom-bff/ 2024-02-21T12:12:44+00:00 https://hieisai.com.ph/wp-content/uploads/2024/02/brush-for-freedom-bff.webp https://hieisai.com.ph/memories-reimagined/ 2024-02-21T12:14:11+00:00 https://hieisai.com.ph/wp-content/uploads/2024/02/memories-reimagined-thumbnail.webp https://hieisai.com.ph/hope-2gether-a-life-repurposed/ 2024-02-21T12:17:26+00:00 https://hieisai.com.ph/wp-content/uploads/2024/02/hope-2-gether-a-life-repurposed-1.webp https://hieisai.com.ph/eisais-approach-to-u-s-pricing-for-leqembi-lecanemab-a-treatment-for-early-alzheimers-disease-sets-forth-our-concept-of-societal-value-of-medicine-in/ 2024-03-20T04:00:51+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/wp-content/uploads/2024/03/e202302-01.png https://hieisai.com.ph/wp-content/uploads/2024/03/e202302-02.png https://hieisai.com.ph/eisais-commitment-to-scientific-evidence-and-patient-safety/ 2024-03-20T04:00:58+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-submits-supplemental-biologics-license-application-to-fda-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease/ 2024-03-20T04:01:06+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/fda-approves-leqembi-lecanemab-irmb-under-the-accelerated-approval-pathway-for-the-treatment-of-alzheimers-disease/ 2024-03-20T04:04:57+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-launches-renewed-sustainability-page/ 2024-03-20T04:27:37+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/wp-content/uploads/2024/03/202306-1e.png https://hieisai.com.ph/eisai-files-marketing-authorization-application-for-anti-amyloid-beta-protofibril-antibody-lecanemab-for-early-alzheimers-disease-in-japan/ 2024-03-20T04:38:24+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe/ 2024-03-20T04:39:00+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-aims-to-advance-gastrointestinal-cancer-treatment-with-research-across-multiple-tumor-types-at-asco-gi-2023/ 2024-03-20T04:50:31+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-commences-business-activities-at-new-pharma-sales-subsidiary-in-israel/ 2024-03-20T05:00:03+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-listed-as-a-global-100-most-sustainable-corporation-for-the-seventh-time/ 2024-03-20T05:00:47+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-accepted-by-european-medicines-agency/ 2024-03-20T05:12:26+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/lecanemab-receives-priority-review-status-in-japan/ 2024-03-20T05:28:55+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/biologics-license-application-for-lecanemab-designated-for-priority-review-by-china-national-medical-products-administration/ 2024-03-20T05:36:20+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/biogen-japan-and-eisai-provide-update-on-co-promotion-of-multiple-sclerosis-treatments-in-japan/ 2024-03-20T05:46:39+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/fda-accepts-eisais-filing-of-a-supplemental-biologics-license-application-and-grants-priority-review-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheim/ 2024-03-20T06:10:26+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-certified-as-a-2023-health-and-productivity-management-outstanding-organization-white-500/ 2024-03-20T06:55:49+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/wp-content/uploads/2024/03/202317-01.jpg https://hieisai.com.ph/eisai-receives-the-basic-achievement-grand-prize-at-the-2023-j-win-diversity-award/ 2024-03-20T06:59:31+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/wp-content/uploads/2024/03/202318-01.jpg https://hieisai.com.ph/u-s-veterans-health-administration-vha-provides-coverage-of-leqembi-lecanemab-irmb-two-months-after-leqembis-fda-accelerated-approval-for-veterans-living-with-early-sta/ 2024-03-20T07:06:49+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-publishes-societal-value-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal/ 2024-03-20T07:55:48+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-present-new-lecanemab-data-including-research-evaluating-safety-profile-clinical-outcomes-and-quality-of-life-measures-as-well-as-other-important-alzheimers-disease-research-at-t/ 2024-03-20T07:59:42+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-invests-in-c2n-to-support-simplifying-the-diagnosis-of-early-alzheimers-disease-to-better-serve-patients/ 2024-03-20T11:19:11+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-present-data-on-lecanemab-and-other-alzheimers-disease-research-at-the-ad-pd-2024-annual-meeting/ 2024-03-20T11:52:36+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-boost-initiatives-on-greenhouse-gas-reductionaiming-to-achieve-net-zero-by-2050/ 2024-03-20T12:08:09+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-selected-for-human-capital-leaders-2023-and-human-capital-management-gold-quality-recognized-as-company-committed-to-excellent-management-and-disclosure-of-h/ 2024-03-20T12:13:44+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/metoject-subcutaneous-injection-pen-methotrexate-pen-type-autoinjector-approved-in-japan/ 2024-03-20T12:30:27+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-commences-fully-fledged-business-activities-at-pharma-sales-subsidiary-in-south-africa/ 2024-03-20T12:39:51+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-submits-new-drug-application-for-mecobalamin-ultrahigh-dose-formulation-in-japan-for-the-indication-of-amyotrophic-lateral-sclerosis/ 2024-03-20T12:44:15+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/antiepileptic-drug-fycompa-injection-formulation-approved-in-japan/ 2024-03-20T12:48:49+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-listed-as-a-global-100-most-sustainable-corporation-for-the-eighth-time/ 2024-03-20T13:06:11+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/the-scientific-advisory-group-sag-to-convene-to-discuss-the-marketing-authorization-application-for-lecanemab-in-the-eu/ 2024-03-21T05:46:38+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/leqembi-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-china/ 2024-03-21T05:57:27+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-furthers-oncology-research-across-multiple-cancers-at-asco-gi-and-asco-gu-2024/ 2024-03-21T06:18:23+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-supports-relief-efforts-for-the-noto-peninsula-earthquake-of-2024-in-japan/ 2024-03-21T06:20:29+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/development-of-prediction-model-for-brain-amyloid-beta-accumulation-using-wristband-sensor/ 2024-03-21T06:35:25+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-submits-marketing-authorization-application-in-japan-for-anticancer-agent-tasurgratinib-for-biliary-tract-cancer-with-fgfr2-gene-fusion/ 2024-03-21T06:43:10+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-present-research-from-oncology-portfolio-at-the-society-of-gynecologic-oncology-sgo-2023-annual-meeting-on-womens-cancer/ 2024-03-22T02:08:40+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-selected-as-a-nadeshiko-brand-2024-as-a-listed-company-excelling-in-promotion-of-women-in-the-workplace/ 2024-03-22T03:33:25+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/wp-content/uploads/2024/03/news202415_01.jpg https://hieisai.com.ph/lifenet-and-eisai-co-develop-dementia-insurance-be/ 2024-03-22T03:49:27+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/wp-content/uploads/2024/03/news202416_01.png https://hieisai.com.ph/additional-detailed-analyses-from-phase-2-study-201-of-lecanemab-published-as-three-papers-in-peer-reviewed-journals/ 2024-03-22T03:58:57+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-presented-new-analyses-of-aria-and-qol-on-lecanemab-in-clarity-ad-at-the-ad-pd-2023-annual-meeting/ 2024-03-22T04:11:46+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-enters-into-agreement-with-national-cancer-center-to-collaborate-on-investigator-initiated-clinical-research-for-anticancer-agent-tazemetostat-based-on-patient-proposed-healthcare-servi/ 2024-03-22T04:24:15+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-publishes-long-term-health-outcomes-using-simulation-model-of-lecanemab-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal/ 2024-03-22T04:28:03+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-completes-a-major-renovation-of-tsukuba-research-laboratories/ 2024-03-22T04:37:47+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/wp-content/uploads/2024/03/202328-01.jpg https://hieisai.com.ph/wp-content/uploads/2024/03/202328-02.jpg https://hieisai.com.ph/wp-content/uploads/2024/03/202328-03.png https://hieisai.com.ph/eisai-and-merck-co-inc-rahway-nj-usa-provide-update-on-phase-3-trials-of-lenvima-lenvatinib-plus-keytruda-pembrolizumab-in-certain-patients-with-advanced-melanoma-leap-003-an/ 2024-03-22T04:45:20+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-enters-into-joint-development-agreement-with-blissbio-for-antibody-drug-conjugate-bb-1701-with-option-rights-for-strategic-collaboration/ 2024-03-22T04:57:25+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/notification-regarding-revision-of-consolidated-financial-forecasts-ifrs-for-the-fiscal-year-ended-march-31-2023/ 2024-03-22T05:00:42+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/notification-regarding-the-revision-of-the-compensation-system-for-directors-and-corporate-officers-and-stock-compensation-system-officers-compensation-bip-trust-and-additional-contribution/ 2024-03-22T05:24:54+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/wp-content/uploads/2024/03/e202332_1.png https://hieisai.com.ph/eisai-and-mizuho-sign-sustainability-linked-loan-agreement/ 2024-03-22T10:12:35+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/1539-2/ 2024-03-22T10:43:20+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-and-merck-co-inc-rahway-nj-usa-provide-update-on-phase-3-leap-001-trial-evaluating-lenvima-lenvatinib-plus-keytruda-pembrolizumab-as-first-line-treatment-for-patients-wit/ 2024-03-22T11:02:29+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisais-sales-subsidiary-collaborates-with-ministry-of-public-health-moph-in-thailand/ 2024-03-22T11:08:34+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-present-latest-data-on-perampanel-at-the-77th-american-epilepsy-society-aes-annual-meeting/ 2024-03-22T11:22:17+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/leqembi-wins-best-new-drug-and-clinical-advance-of-the-year-at-the-scrip-awards-2023/ 2024-03-22T11:28:16+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-named-as-greatest-ir-improvement-premium-company-and-best-continual-ir-efforts-premium-company-at-the-japan-investor-relations-association-30th-anniversary-co/ 2024-03-22T11:32:14+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-presents-new-leqembi-lecanemab-irmb-investigational-subcutaneous-formulation-interim-study-results-and-clinical-improvement-data-in-earlier-stages-of-early-alzheimers-disease-fr/ 2024-03-22T11:50:48+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/leqembi-lecanemab-irmb-named-one-of-times-best-inventions-of-2023/ 2024-03-22T12:00:55+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-present-new-data-from-leqembi-lecanemab-irmb-phase-3-clarity-ad-study-and-other-alzheimers-disease-pipeline-research-at-the-clinical-trials-on-alzheimers-disease-ctad-con/ 2024-03-22T12:20:11+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-present-research-from-oncology-portfolio-and-pipeline-at-esmo-congress-2023/ 2024-03-22T12:36:56+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/notice-of-absorption-type-merger-simplified-merger-short-form-merger-of-kan-research-institute-inc/ 2024-03-22T12:47:22+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-launches-new-innovation-page-on-corporate-website/ 2024-03-22T12:54:19+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/tokio-marine-nichido-and-eisai-co-develp-industrys-first-dementia-care-support-insurance/ 2024-03-22T13:11:31+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/leqembi-intravenous-infusion-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-japan/ 2024-03-22T13:25:44+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-and-merck-co-inc-rahway-nj-usa-provide-update-on-two-phase-3-trials-evaluating-lenvima-lenvatinib-plus-keytruda-pembrolizumab-in-patients-with-certain-types-of-metastatic/ 2024-03-25T04:13:20+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/release-of-dementia-disease-awareness-videos-for-world-alzheimers-day-september-21-life-goes-on-2023-two-memories-one-story/ 2024-03-25T04:24:10+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-establishes-theoria-technologies-co-ltd-a-new-digital-business-company-to-build-a-dementia-ecosystem/ 2024-03-25T04:29:37+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-and-merck-co-inc-rahway-nj-usa-provide-update-on-phase-3-leap-010-trial-evaluating-lenvima-lenvatinib-plus-keytruda-pembrolizumab-in-patients-with-certain-types-of-recurr/ 2024-03-25T04:47:24+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-listed-for-22nd-consectutive-year-in-ftse4good-index-series-an-index-for-socially-responsible-investment/ 2024-03-25T04:54:19+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/organizational-reform-and-changes-of-corporate-officers/ 2024-03-25T05:00:14+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-presents-latest-analysis-of-lecanemabs-effect-on-biomarker-changes-and-subcutaneous-dosing-at-the-alzheimers-association-international-conference-aaic-2023/ 2024-03-25T05:12:23+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-present-the-latest-alzheimers-disease-pipeline-and-research-including-lecanemab-and-anti-mtbr-tau-antibody-e2814-at-the-alzheimers-association-international-conference-aa/ 2024-03-25T05:34:48+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/changes-of-corporate-officers/ 2024-03-25T05:38:47+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/fda-grants-traditional-approval-for-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease/ 2024-03-25T06:12:55+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-transfers-all-future-economic-rights-for-elacestrant-a-selective-estrogen-receptor-degrader-to-dri-healthcare/ 2024-03-25T06:16:30+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/position-and-policy-regarding-reduction-of-the-investment-unit-of-the-companys-shares/ 2024-03-25T06:19:31+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/new-neurii-research-collaboration-between-eisai-gates-ventures-health-data-research-uk-lifearc-and-the-university-of-edinburgh-to-develop-digital-solutions-for-dementia-is-announced/ 2024-03-25T06:27:22+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisais-nouknow-will-continue-to-be-utilized-for-brain-health-assessment-as-part-of-the-fy2023-dementia-examination-project-by-tokyo-bunkyo-city/ 2024-03-25T06:37:18+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-files-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-south-korea/ 2024-03-25T06:57:41+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/fda-advisory-committee-votes-unanimously-to-confirm-the-clinical-benefit-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease/ 2024-03-25T06:57:51+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/notification-of-ransomware-incident/ 2024-03-25T06:59:47+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-present-latest-data-on-lemborexant-at-the-37th-annual-sleep-2023-meeting/ 2024-03-25T07:04:34+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/lenvima-lenvatinib-plus-keytruda-pembrolizumab-demonstrates-long-term-durable-survival-benefit-versus-sunitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma/ 2024-03-25T07:20:32+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisais-initiatives-for-developing-new-medicines-for-neglected-tropical-diseases-and-malaria-and-commitment-for-funding-to-the-3rd-phase-of-global-health-innovative-technology-fund-activities/ 2024-03-25T07:23:17+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-great-britain/ 2024-03-25T07:34:38+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-delivers-new-data-and-highlights-continued-progress-of-oncology-portfolio-and-pipeline-at-asco-2023/ 2024-03-25T07:34:52+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-publishes-societal-value-of-lecanemab-in-japan-using-phase-3-clarity-ad-data-in-peer-reviewed-neurology-and-therapy-journal/ 2024-03-25T07:38:27+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/health-canada-accepts-new-drug-submission-for-lecanemab-as-treatment-for-early-alzheimers-disease/ 2024-03-25T07:45:21+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/yasuda-logistics-and-eisai-enters-agreement-to-transfer-eisais-subsidiary-eisai-distribution-to-yasuda-logistics/ 2024-03-27T08:15:16+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/article-regarding-safety-information-of-lecanemab-reported-by-scienceinsider/ 2024-03-27T08:17:20+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-initiates-bla-submission-of-data-for-lecanemab-in-china/ 2024-03-27T08:22:09+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/astellas-eisai-daiichi-sankyo-and-takeda-agree-to-collaborate-to-reduce-environmental-burden-in-the-field-of-pharmaceutical-packaging/ 2024-03-27T08:25:55+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-divest-rights-for-anti-epileptic-drug-fycompa-perampanel-ciii-in-united-states-to-catalyst-pharmaceuticals/ 2024-03-27T08:29:43+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-terminates-sponsored-american-depositary-receipt-program/ 2024-03-27T08:34:47+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-and-washington-university-school-of-medicine-in-st-louis-enter-into-comprehensive-research-collaboration-agreement-aiming-to-create-new-therapies-for-neurodegenerative-diseases/ 2024-03-27T08:37:16+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-present-preclinical-and-clinical-research-on-eribulin-at-the-2022-san-antonio-breast-cancer-symposium/ 2024-03-27T08:47:58+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-presents-full-results-of-lecanemab-phase-3-confirmatory-clarity-ad-study-for-early-alzheimers-disease-at-clinical-trials-on-alzheimers-disease-ctad-conference/ 2024-03-27T09:04:46+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eleven-experts-from-leading-medical-institutions-and-eight-experts-from-eisai-publish-full-results-of-lecanemab-phase-3-confirmatory-clarity-ad-study-for-early-alzheimers-disease-in-the-new/ 2024-03-27T09:18:24+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/revision-article-regarding-safety-information-of-lecanemab-reported-by-scienceinsider/ 2024-03-27T09:23:15+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-announces-approval-of-partial-change-to-label-for-dosage-and-administration-of-aricept-for-treatment-of-dementia-with-lewy-bodies/ 2024-03-27T09:36:14+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-present-latest-data-on-perampanel-at-the-76th-american-epilepsy-society-aes-annual-meeting/ 2024-03-27T09:40:52+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/to-develop-japans-first-blood-biomarker-based-diagnostic-workflow-for-dementia-shimadzu-eisai-oita-university-and-usuki-city-medical-association-commence-joint-research/ 2024-03-27T10:02:52+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png https://hieisai.com.ph/eisai-to-present-full-findings-from-lecanemab-confirmatory-phase-3-clinical-trial-clarity-ad-and-other-alzheimers-disease-research-at-the-15th-clinical-trials-on-alzheimers-disease-ctad/ 2024-03-27T10:22:26+00:00 https://hieisai.com.ph/wp-content/uploads/2023/09/hi-eisai-big-logo.png